News from janssen biotech, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Jul 06, 2015, 08:20 ET

Daratumumab Expanded Access Program Open to Eligible U.S. Patients with Heavily Pre-Treated Multiple Myeloma

 Janssen Biotech, Inc. (Janssen) announced today the opening of a daratumumab expanded access program (EAP) for eligible U.S. patients....

Jun 03, 2015, 08:07 ET
Television and film actress Megan Park announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly disclosed living with a chronic autoimmune disease. Park made the announcement in partnership with Joint Decisions.

Actress Megan Park Shares Private Struggle With Rheumatoid Arthritis For The First Time Through "Joint Decisions" Educational Program

 Television and film actress Megan Park today announced that she lives with rheumatoid arthritis (RA), marking the first time she has publicly...

Jan 29, 2015, 11:48 ET

U.S. FDA Approves IMBRUVICA® (ibrutinib) for the Treatment of Waldenstrom's Macroglobulinemia: First FDA-Approved Therapy for This Disease

Janssen Biotech, Inc. ("Janssen") today announced that the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA®...

Oct 27, 2014, 08:00 ET
Sunny Anderson, celebrity cook, television host and ulcerative colitis patient

Celebrity Cook Sunny Anderson Teams Up With Janssen And Crohn's & Colitis Foundation Of America To Launch Educational Campaign

Janssen Biotech, Inc. and the Crohn's & Colitis Foundation of America (CCFA) announced today the launch of Get Your Full Course, an educational...

Jul 28, 2014, 13:24 ET
IMBRUVICA(R) (ibrutinib) 140mg capsules. (PRNewsFoto/Janssen Biotech, Inc.)

IMBRUVICA® (ibrutinib) Receives Regular Approval by U.S. FDA in Chronic Lymphocytic Leukemia (CLL) and CLL patients with del 17p

The U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for IMBRUVICA® (ibrutinib) capsules for...

Apr 23, 2014, 17:17 ET
SYLVANT 100 and 400 mg Vials (PRNewsFoto/Janssen Biotech, Inc.)

SYLVANT™ (siltuximab) Receives FDA Approval to Treat Multicentric Castleman's Disease (MCD)

 Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved SYLVANT™ (siltuximab) for the...

Feb 12, 2014, 13:37 ET
IMBRUVICA(TM) (ibrutinib) 140mg capsules.  (PRNewsFoto/Janssen Biotech, Inc.)

IMBRUVICA™ (ibrutinib) Now Approved in the U.S. for Patients with Chronic Lymphocytic Leukemia Who Have Received At Least One Prior Therapy

 Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib)...

Nov 13, 2013, 12:48 ET

IMBRUVICA™ (ibrutinib) Capsules Now Approved in the U.S. for Mantle Cell Lymphoma Patients Who Have Received at Least One Prior Therapy

Janssen Biotech, Inc. ["Janssen"] today announced the U.S. Food and Drug Administration (FDA) has approved IMBRUVICA™ (ibrutinib) capsules...

Oct 28, 2013, 08:10 ET

New Two-year Results Show SIMPONI® ARIA™ (golimumab) For Infusion Inhibited Radiographic Progression In Patients With Active Rheumatoid Arthritis

 New two-year results of a Phase 3 study sponsored by Janssen Research & Development, LLC (Janssen) showed that SIMPONI®...

Sep 23, 2013, 07:30 ET

STELARA® (ustekinumab) Receives FDA Approval To Treat Active Psoriatic Arthritis

 Janssen Biotech, Inc., announced today that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) alone or in...

Jul 18, 2013, 19:04 ET

SIMPONI® ARIA™ (golimumab) For Infusion Receives FDA Approval For Treatment Of Moderately To Severely Active Rheumatoid Arthritis

Janssen Biotech, Inc. announced today the U.S. Food and Drug Administration (FDA) approval of SIMPONI® ARIATM (golimumab) for infusion for the...

Jun 27, 2013, 07:07 ET
Jun 12, 2013, 08:00 ET

Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis

 Janssen Biotech, Inc. announced today new five-year data from three pivotal Phase 3 studies evaluating SIMPONI® (golimumab) 50 mg...

May 15, 2013, 16:15 ET

SIMPONI® (golimumab) Receives FDA Approval for Ulcerative Colitis

 Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI® (golimumab) for the...

Apr 18, 2013, 08:00 ET

Richard Petty Teams Up With Janssen Biotech to Launch Show Your Stripes for Prostate Cancer Awareness

Legendary NASCAR® driver, team owner, and prostate cancer survivor Richard Petty has teamed with Janssen Biotech, Inc. on Show Your Stripes...

Dec 10, 2012, 13:39 ET

U.S. FDA Approves Expanded ZYTIGA® Indication for Treatment of Metastatic Castration-Resistant Prostate Cancer

Janssen announced today that the U.S. Food and Drug Administration (FDA) has approved a broader indication for the oral, once-daily medication...

Dec 06, 2012, 08:00 ET

Janssen Submits Applications Requesting Approval Of STELARA® In U.S. And Europe For Treatment Of Active Psoriatic Arthritis

 Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the...

Nov 08, 2012, 10:43 ET

What Men Should Know About Prostate Cancer -- But Don't

 While the devastating physical effects of prostate cancer are widely known, the psychological impact of the disease is a silent struggle for...

Oct 01, 2012, 19:00 ET

Janssen Announces Worldwide Agreement To Develop And Commercialize JAK Inhibitor For Immunological Diseases

 Janssen Biotech, Inc. ("Janssen") announced today that it has entered into a license agreement with Astellas Pharma Inc. ("Astellas") for the...

Sep 18, 2012, 17:01 ET

Janssen Submits Application To FDA Requesting Approval Of SIMPONI® Intravenous Formulation For Treatment Of Moderately To Severely Active Rheumatoid Arthritis

 Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)...